Humanity will always depend on medicines. Continuous innovation in the biotech sector is a given. Bringing better medicines to the market all the time. Aescap is able to select those companies that are developing tomorrow’s medicines. Thereby it can achieve excellent returns over the medium term, without taking large risks.
The Aescap funds invest in highly innovative publicly traded biotech/life sciences companies. The funds are supervised by an AIFM and managed by an experienced investment team with an excellent track record. The members of the investment team significally invest in the funds themselves. Aescap is heavily involved with the companies it invests in, acting as a private equity investor on the stock market. The name Aescap is derived from ‘Aesculapius’, the Roman god of Medicine, and ‘Capital’.
The companies in the portfolios of the Aescap biotech funds address medical needs that are not met by products available today. We believe everybody has the right to receive the best medical care available. Aescap’s investments have positively affected society and have already resulted in an improvement of the quality of life of millions of people worldwide.
Both Aescap Funds are classified as article 8 fund, according to the Sustainable Finance Disclosure Regulation (SFDR).
We regularly organise information meetings for existing and potential investors. In these meetings we share our investment philosophy as well as methodology. The next meeting takes place on December 19th.
The Aescap investment team, led by portfolio manager Patrick Krol, consists of experienced professionals with different backgrounds in the health care industry. We aim to provide a good financial return to our investors, and in parallel contribute to improving the well-being of millions of people. Our team members invest in the Aescap funds themselves with over 25 million euro.
The biotech sector, also known as the life sciences sector, is a large and fast-growing sector, driven by an aging population and a high pace of innovation. New medicines like RNA, gene and cell therapies will replace the vast majority of medicine over the coming decades. With around 1000 public biotech companies in the EU and US, it requires sector specific expertise to find de-risked companies with a high earning power that are still undervalued.
Aescap portfolio company Rocket Pharmaceuticals yesterday went up 39% after it came to an agreement with the FDA that it only needs to enroll 12 patients in a pivotal clinical trial with their gene therapy for a fatal heart disease.
Promising undervalued biotech companies offer an excellent opportunity for significant future returns. Waiting until the sector is back in the spotlight often results in a missed opportunity. As share prices will have risen by then.